Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 41-81 CAG repeats, compared to 6-39 in the normal allele. At least two transcript variants encoding the same protein have been found for this gene.Tissue specificity: Widely expressed throughout the body.
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000; ICC: 1/200 - 1/1000; FCM: 1/200 - 1/400
Size: 100 ul, 1mg/ml
Species Reactivity: Human
Isotype: Mouse IgG1
Immunogen: Purified recombinant fragment of human ATXN1 expressed in E. Coli.
Formulation: Ascitic fluid containing 0.03% sodium azide.
Storage: 4C; -20C for long term storage
Spplier link: http://www.promab.com/index.php?main_page=product_info&products_id=545
Reference: 1. Nature. 2008 Apr 10;452(7188):713-8. ; 2. Biochem Biophys Res Commun. 2008 Jun 27;371(2):256-60. ; 3. Indian J Med Res. 2007 Nov;126(5):465-70.